Cardiovascular prevention and blood pressure reduction: A quantitative overview updated until 1 March 2003

Journal of Hypertension

Volumn 21, Issue 6, 2003, Pages 1055-1076

  Staessen, Jan A ^a,b   Wang, Ji Guang ^a   Thijs, Lutgarde ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Blood pressure; Clinical trial; Heart failure; Morbidity; Mortality; Myocardial infarction; Prevention; Stroke

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; LISINOPRIL; LOSARTAN; VERAPAMIL;

ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; GENETIC HETEROGENEITY; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; META ANALYSIS; MORTALITY; OUTCOMES RESEARCH; PREDICTION; PRIORITY JOURNAL; PROPHYLAXIS; QUANTITATIVE ANALYSIS; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; STROKE; SYSTOLIC BLOOD PRESSURE;

EID: 0038203004     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200306000-00002     Document Type: Article

References (134)

1. Staessen JA, Wang JG, Thijs L. Cardiovascular prevention and blood pressure reduction: a meta-analysis. Lancet 2001; 358:1305-1315 [erratum published in the Lancet 2002; 359:360].
2. Staessen JA, Wang JG, Thijs L. Calcium-channel blockade and cardiovascular prognosis: recent evidence from clinical outcome trials. Am J Hypertens 2002; 15:85S-93S.
3. Borhani NO, Mercuri M, Borhani PA, Buckalew VM, Canossa-Terris MCAA, Kappagoda T, et al. Final outcome results of the multicenter isradipine diuretic atherosclerosis study (MIDAS). A randomized controlled trial. JAMA 1996; 276:785-791.
4. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353:611-616.
5. National Intervention Cooperative Study in Elderly Hypertensives Study Group. Randomized double-blind comparison of a calcium antagonist and a diuretic in elderly hypertensives. Hypertension 1999; 34:1129-1133.
6. Hansson L, Lindholm LH, Ekbom T, Dahlöf B, Lanke J, Soherstén B, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity in the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999; 354:1751-1756.
7. Brown MJ, Palmer CR, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T, et al. Morbidity and mortality in patients randomised to double-blind treatment with long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS Study: Intervention as a Goal in Hypertensive Treatment (INSIGHT). Lancet 2000; 356:366-372.
8. Hansson L, Hedner T, Lund-Johansen P, Kjeldsen SE, Lindholm LH, Syvertsen JO, et al. Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000; 356:359-365.
9. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2000; 283:1967-1975.
10. Zanohetti A, Agabiti Rosei E, Dal Palú C, Leonetti G, Magnani B, Pessina A, et al. The Verapamil in Hypertension and Atherosolerosis Study (VHAS): results of long-term randomized treatment with either verapamil or chlorthalidone on carotid intima-media thickness. J Hypertens 1998; 16:1667-1676.
11. UK Prospective Diabetes Study Group. Efficacy of atenolol and oaptopril in reducing risk of maorovasoular and miorovasoular oomplications in type 2 diabetes: UKPDS 39. BMJ 2000; 317:713-720.
12. Amery A, Birkenhäger W, Brixko P, Bulpitt C, Clement D, Deruyttere M, et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet 1985; i:1349-1354.
13. European Working Party on High Blood Pressure in the Elderly (EWPHE). An international trial of antihypertensive therapy in elderly patients. Objectives, protocol and organization. Arch Int Pharmacodyn Ther 1985; 275:300-334.
14. Coope J, Warrender TS. Randomised trial of treatment of hypertension in elderly patients in primary care. BMJ 1986; 293:1145-1151.
15. Dahlöf B, Lindholm LH, Hansson L, Soherstén B, Ekbom T, Wester PO. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP·Hypertension). Lancet 1991; 338:1281-1285.
16. MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ 1992; 304:405-412.
17. Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. BMJ 1985; 291:97-104.
18. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265:3255-3264.
19. Gong L, Zhang W, Zhu Y, Zhu J, 11 collaborating centres in the Shanghai area, Kong D, et al. Shanghai Trial Of Nifedipine in the Elderly (STONE). J Hypertens 1996; 14:1237-1245.
20. Curb JD, Pressel SL, Cutler JA, Savage PJ, Applegate WB, Black H, et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA 1996; 276:1886-1892.
21. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhäger WH, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997; 350:757-764 (erratum published in the Lancet 1997; 350:1636].
22. Management Committee. The Australian Therapeutic Trial in Mild Hypertension. Lancet 1980; i:1261-1267.
23. PATS Collaborative Group. Post-stroke antihypertensive treatment study. A preliminary result. Chin Med J 1995; 108:710-717.
24. Hansson L, Hedner T, Lindholm L, Niklason A, Luomanmäki K, Niskanen L, et al. The Captopril Prevention Project (CAPPP) in hypertension-baseline data and current status. Blood Press 1997; 6:365-367.
25. Davis BR, Cutler JA, Gordon DJ, Furberg CD, Wright JT Jr, Cushman WC, et al. Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Am J Hypertens 1996; 9:342-360.
26. Helgeland A. Treatment of mild hypertension: a five year controlled drug trial. Am J Med 1980; 69:725-732.
27. Hypertension-Stroke Cooperative Study Group. Effect of antihypertensive treatment on stroke recurrence. JAMA 1974; 229:409-418.
28. US Public Health Service Hospitals Cooperative Study Group (McFate Smith WM). Treatment of mild hypertension: results of a ten-year intervention trial. Circ Res 1977; 40:198-1105.
29. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effect of treatment on morbidity in hypertension: results in patients with diastolic blood pressure averaging 115-129 mm Hg. JAMA 1967; 202:116-122.
30. Liu L, Wang JG, Gong L, Liu G, Staessen JA, for the Systolic Hypertension in China (Syst-China) Collaborative Group. Comparison of active treatment and placebo in older patients with isolated systolic hypertension. J Hypertens 1998; 16:1823-1829.
31. Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, et al. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351:1755-1762.
32. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317:703-713.
33. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342:145-153.
34. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355:253-259.
35. Agabiti Rosei E, Dal Palú C, Leonetti G, Magnani B, Pessina A, Zanchetti A, et al. Clinical results of the Verapamil in Hypertension and Atherosclerosis Study. J Hypertens 1997; 15:1337-1344.
36. MacMahon S, Sharpe N, Gamble G, Clague A, Ni Mhurchu C, Clark T, et al. Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease. J Am Coll Cardiol 2000; 36:438-443.
37. Teo KK, Burton JR, Buller CE, Plante S, Catellier D, Tymchak W, et al. Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis. The Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT). Circulation 2000; 102:1748-1754.
38. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood pressure lowering regimen among 6105 individuals with prior stroke or transient ischaemic attack. Lancet 2001; 358:1033-1041.
39. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345:861-869.
40. Staessen JA, Wang JG. Blood-pressure lowering for the secondary prevention of stroke. Lancet 2001; 358:1026-1027.
41. Management Committee on behalf of the High Blood Pressure Research Council of Australia. Australian comparative outcome trial of angiotensin-converting enzyme inhibitor- and diuretic-based treatment of hypertension in the elderly (ANBP2): objectives and protocol. Clin Exp Pharmacol Physiol 1997; 24:188-192.
42. Byington RB, Miller ME, Herrington D, Riley W, Pitt B, Furberg CD, et al. Rationale, design, and baseline characteristics of the Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial (PREVENT). Am J Cardiol 1997; 80:1087-1090.
43. Estacio RO, Savage S, Johnson Nagel N, Schrier RW. Baseline characteristics of participants in the Appropriate Blood Pressure Control in Diabetes trial. Control Clin Trials 1996; 17:242-257.
44. Pitt B, Byington RP, Furberg CD, Hunninghake DB, Mancini J, Miller ME, et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. Circulation 2000; 102:1503-1510.
45. Agodoa LY, Appel L, Bakris GL Beck G, Bourgoignie J, Briggs JP, et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis. JAMA 2001; 285:2719-2728.
46. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345:851-860.
47. Zanchetti A, Bond G, Hennig M, Neiss A, Mancia G, Dal Palú, C, et al. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis. Principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation 2002; 106:r47-r52.
48. Lindholm LH, Ibsen H, Dahlöf B, Devereux RB, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:1004-1010.
49. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:995-1003.
50. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288:2981-2997.
51. Schrier RW, Estacio RO, Esler A, Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 2002; 61:1086-1097.
52. Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel U, Charleston J, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease. Results from the AASK trial. JAMA 2002; 288:2421-2431.
53. Zanchetti A, Bond MG, Hennig M, Neiss A, Mancia G, Dal Palú C, et al. Risk factors associated with alterations in carotid intima-media thickness in hypertension: baseline data from the European Lacidipine Study on Atherosclerosis. J Hypertens 1998; 16:949-961.
54. Rodby RA, Rohde RD, Clarke WR, Hunsicker LG, Anzalone DA, Atkins RC, et al. The Irbesartan Type II Diabetic Nephropathy Trial: study design and baseline patient characteristics. Nephrol Dial Transplant 2000; 15:487-497.
55. Wing LMH, Reid CM, Ryan P, Beilin LJ, Brown MA, Jennings GLR, et al. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003; 348:583-592.
56. Bulpitt CJ, Fletcher AE, Amery A, Coope J, Evans JG, Lightowlers S, et al. The Hypertension in the Very Elderly Trial (HYVET). Rationale, methodology and comparison with previous trials. Drugs Aging 1994; 5:171-183.
57. Black HR, Elliott WJ, Neaton JD, Grandits G, Grambsch P, Grimm RH Jr, et al. Rationale and design for the controlled onset verapamil investigation of cardiovascular endpoints (CONVINCE) trial. Control Clin Trials 1998; 19:370-390.
58. Hansson L, Lithell H, Skoog I, Baro F, Bánki CM, Breteler M, et al. Study on COgnition and Prognosis in the Elderly (SCOPE). Blood Press 1999; 8:177-183.
59. Beckett NS, Connor M, Sadler JD, Fletcher AE, Bulpitt CJ, on behalf of the HYVET Investigators. Orthostatic fall in blood pressure in the very elderly hypertensive: results from the Hypertension in the Very Elderly Trial (HYVET) - pilot. J Hum Hypertens 1999; 13:839-840.
60. Black HR, Elliott WJ, Grandits G, Grambsch P, Lucente T, White WB, et al. Principal results of the Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints (CONVINCE) Trial. JAMA 2003; 289:2073-2082.
61. Dens JA, Desmet WJ, Coussement P, De Scheerder IK, Kostopoulos K, Kerdsinchai P, et al. Usefulness of nisoldipine for prevention of restenosis after percutaneous transluminal coronary angioplasty (results of the NICOLE study). Nisoldipine in COronary artery disease in LEuven. Am J Cardiol 2001; 87:28-33.
62. Lièvre M, Marre M, Chatellier G, Plouin PF, Réglier JC, Richardson L, et al. The non-insulin-dependent diabetes, hypertension, microalbuminuria or proteinuria, cardiovascular events, and ramipril (DIABHYCAR) Study: design, organization, and patient recruitment. Control Clin Trials 2000; 21:383-396.
63. Marre M, Lièvre M, Vasmant D, Gallois Y, Hadjadj S, Réglier JC, et al. Determinants of elevated urinary albumin in the 4,937 type 2 diabetic subjects recruited for the DIABHYCAR study in Western Europe and Northern Africa. Diabet Care 2000; 23 (suppl 2):B40-B48.
64. Marre M, Lièvre M, Chatellier G, Vasmant D, Mann J, Passa P, et al. Low-dose ramipril (1.25 mg/day) does not decrease cardiovascular events in type 2 diabetes patients with microalbuminuria/proteinuria: the DIABHYCAR (type 2 DIABetes, HYpertension, CARdiovascular events and Ramipril) study, http://www.easd.org/abstracts/OP31.html (accessed on 1 September 2002).
65. Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, et al. The study on cognition and prognosis in the elderly (SCOPE). Principal results of a randomised double-blind intervention trial. J Hypertens 2003; 21:875-886.
66. Casiglia E, Spolaore P, Mazza A, Ginocchio G, Colangeli G, Onesto C, et al. Effect of 2 different therapeutic approaches on total and cardiovascular mortality in a cardiovascular study in the elderly. Jpn Heart J 1994; 35:589-600.
67. Neaton JD, Grimm RH Jr, Prineas RJ, Stamler J, Grandits GA, Elmer PJ, et al. Treatment of mild hypertension study: final results. JAMA 1993; 270:713-724.
68. Wright JT, Kusek JW, Toto RD, Lee JY, Agodoa LY, Kirk KA, et al. Design and baseline characteristics of participants in the African American Study of Kidney disease and hypertension (AASK) pilot study. Control Clin Trials 1996; 16:3S-16S.
69. Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, et a. Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. J Hypertens 2001; 19:1139-1147.
70. Bond G, Dal Palú C, Hansson L, Magnani B, Mancia G, Neiss A, et al. The E.L.S.A. Trial: protocol of a randomized trial to explore the differential effect of antihypertensive drugs on atherosclerosis in hypertension. J Cardiovasc Pharmacol 1994; 23 (suppl 5):S85-S87.
71. Pepihe CJ, Handberg-Thurmond E, Marks RG, Conlon M, Cooper-DeHoff R, Volkers P, et al. Rationale and design of the International Verapamil SR/Trandolapril Study (INVEST): an internet-based randomized trial in coronary heart disease patients with hypertension. J Am Coll Cardiol 1998; 32:1228-1337.
72. Dahlöf B, Devereux R, de Faire U, Fyhrquist F, Hedner T, Ibsen H, et al. The Losartan Intervention For Endpoint reduction (LIFE) in hypertension study: rationale, design and methods. Am J Hypertens 1997; 10:705-713.
73. Lindholm LH, Ibsen H, Borch-Johnsen K, Olsen MH, Wachtell K, Dahlöf B, et al. Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens 2002; 20:1879-1886.
74. Zanchetti A, Crepaldi G, Bond MG, Gallus GV, Veglia F, Ventura A, et al. Systolic and pulse pressures (but not diastolic blood pressure and serum cholesterol) are associated with alterations in carotid intimamedia thickness in the moderately hypercholesterolaemic hypertensive patients of the Plaque Hypertension Lipid Lowering Italian Study. J Hypertens 2001; 19:79-88.
75. Brookes L. The Plaque HYpertensfon Lipid-Lowering Italian Study (PHYLLIS). Medscape http://www.medscape.com/viewarticle/438432 (accessed on 30 September 2002).
76. Zanchetti A. Evaluating the benefits of an antihypertensive agent using trials based on event and organ damage: the Systolic Hypertension in the Elderly Long-term Lacidipine (SHELL) trial and the European Lacidipine Study on Atherosclerosis. J Hypertens 1995; 13 (suppl 4):S35-S39.
77. The IPPPSH Collaborative Group. Cardiovascular risk and risk factors in a randomized trial of treatment based on the beta-blocker oxprenolol: the International Primary Prevention Study in Hypertension (IPPPSH). J Hypertens 1985; 3:379-392.
78. Wilhelmsen L, Berglund G, Elmfeldt D, Fitzsimons T, Holzgreve H, Hosie J, et al. Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY trial. J Hypertens 1987; 5:561-572.
79. Wikstrand J, Westergren G, Berglund G, Bracchetti D, Van Couter A, Feldstein CA, et al. Antihypertensive treatment with metoprolol or hydrochlorothiazide in patients aged 60 to 75 years. Report from a double-blind international multicenter study. JAMA 1986; 255:1304-1310.
80. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998; 338:645-652.
81. Tatti P, Pahor M, Byington RB, Di Mauro P, Guarisco R, Strollo G, et al. Outcome results of the Fosinopril versus Amlodipine Cardiovascular Events randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998; 21:597-603.
82. Estacio RO, Jeffers BW, Gifford N, Schrier RW. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 2000; 23 (suppl 2):B54-B64.
83. Schrier RW, Estacio RO. Additional follow-up from the ABCD trial in patients with type 2 diabetes and hypertension. N Engl J Med 2000; 343:1969.
84. Kawai C, Yui Y, Hosada S. Large scale multicenter cooperative study for cardiovascular therapy (Japan Multicenter Investigation Drugs/Therapies, J-MIC) - results and perspectives [in Japanese]. Nippon Rinsho 1994; 52:1937-1946.
85. Sprackling ME, Mitchell JRA, Short AH, Watt G. Blood pressure reduction in the elderly: a randomised controlled trial of methyldopa. BMJ 1981; 283:1151-1153.
86. Veterans Administration-NHLBI Study Group for Cooperative Studies on Antihypertensive Therapy: Mild Hypertension (Perry HM Jr). Treatment of mild hypertension: preliminary results of a two-year feasibility trial. Circ Res 1977; 40:1180-1187.
87. Barraclough M, Joys MD, MacGregor GA, Foley TH, Lee MR, Rosendorff C, et al. Control of moderately raised blood pressure: report of a co-operative randomized controlled trial. BMJ 1973; 3:434-436.
88. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA 1970; 213:1143-1152.
89. Wolff FW, Lindeman RD. Effects of treatment in hypertension: results of a controlled study. J Chron Dis 1966; 19:227-240.
90. Carter AB. Hypotensive therapy in stroke survivors. Lancet 1970; 1:485-489.
91. Kuramoto K, Matsushita S, Kuwajima I, Murakami M. Prospective study on the treatment of mild hypertension in the aged. Jpn Heart J 1981; 22:75-85.
92. Hypertension Detection and Follow-up Program Cooperative Group. Five-year findings of the Hypertension Detection and Follow-up Program. I. Reduction in mortality of persons with high blood pressure, including mild hypertension. JAMA 1979; 242:2562-2571.
93. Cashin-Hemphill L, Holmvang G, Chan RC, Pitt B, Dinsmore RE, Lees RS, et al. Angiotensin-converting enzyme inhibition as anti-atherosclerotic therapy: no answer yet. Am J Cardiol 1999; 83:43-47.
94. Wang JG, Staessen JA, Gong L, Liu L, for the Systolic Hypertension in China (Syst-China) Collaborative Group. Chinese trial on isolated systolic hypertension in the elderly. Arch Intern Med 2000; 160:211-220.
95. Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345:870-878.
96. Tuomilehto J, Rastenyte D, Birkenhäger WH, Thijs L, Antikainen R, Bulpitt CJ, et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. N Engl J Med 1999; 340:677-684
97. Staessen JA, Thijs L, Birkenhäger WH, Bulpitt C J, Fagard R, on behalf of the Syst-Eur Investigators. Update on the Systolic Hypertension in Europe (Syst-Eur) Trial. Hypertension 1999; 33:1476-1477.
98. Collins R, MacMahon S. Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease. Br Med Bull 1994; 50:272-298.
99. Mehta C, Patel N. Stratified 2 × 2 contingency tables. In: StatXact 4 for Windows. Statistical software for exact nonparametric inference. User manual. Cambridge, Massachusetts, USA: CYTEL Software Corporation; 1998:469-496.
100. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7:177-188.
101. Thijs L, Fagard R, Lijnen P, Staessen J, Van Hoof R, Amery A. Why is antihypertensive drug therapy needed in elderly patients with systolodiastolic hypertension? J Hypertens 1994; 12 (suppl 6):S25-S34.
102. Staessen JA, Wang JG. Characteristics of published, ongoing, and planned outcome trials in hypertension. In: Oparil S, Weber MA (editors): Hypertension: A companion to Brenner and Rector's The Kidney. 1st ed. Philadelphia, Pennsylvania, USA: W.B. Saunders Company; 1999:341-359.
103. Staessen JA, Gasowski J, Wang JG, Thijs L, Den Hond E, Boissel JP, et al. Risks of untreated and treated isolated systolic hypertension in the elderly; meta-analysis of outcome trials. Lancet 2000; 355:865-872.
104. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet 2000; 355:1955-1964.
105. Pahor M, Psaty BM, Alderman MH, Applegate WB, Williamson JD, Cavazzini C, et al. Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies. Lancet 2000; 356:1949-1954.
106. Hedges LV, Olkin I. Statistical methods for meta-analysis. San Diego, California, USA: Academic Press Inc.; 1985, pp. 223-246.
107. Mancia G, Brown M, Castaigne A, de Leeuw P, Palmer CR, Rosenthal T, et al. Outcomes with nifedipine GITS or co-amilozide in hypertensive diabetics and nondiabetics in Intervention as a Goal in Hypertension (INSIGHT). Hypertension 2003; 41:431-436.
108. World Health Organization-International Society of Hypertension Blood Pressure Lowering Treatment Trialists' Collaboration. Protocol for prospective collaborative overviews of major randomized trials of blood-pressure-lowering treatments. J Hypertens 1998; 16:127-137.
109. Reugg UT, Wallnofer A, Weir S, Cauvin C. Receptor-operated calcium-permeable channels in vascular smooth muscle. J Cardiovasc Pharmacol 1989; 14 (suppl 6):S49-S58.
110. Eriksson S, Olofsson BO, Wester PO, for the TEST Study Group. Atenolol in the secondary prevention of stroke. Cerebrovasc Dis 1995; 5:21-25.
111. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360:1903-1913.
112. Bronner LL, Kanter DS, Manson JE. Primary prevention of stroke. N Engl J Med 1995; 333:1392-1400.
113. Rousseau MF, Melin J, Benedict CR, Ahn S, Raphaël D, Bornemann M, et al. Effects of nisoldipine therapy on myocardial perfusion and neurohumoral status in patients with severe ischaemic left ventricular dysfunction. Eur Heart J 1994; 15:957-964.
114. Thrackray S, Witte K, Clark AL, Cleland JGF. Clinical trials update: OPTIME-CHF, PRAISE-2, ALLHAT. Eur J Heart Failure 2000; 2:209-212.
115. Packer M, O'Connor CM, Ghali JK, Pressler ML, Carson PE, Belkin RN, et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med 1996; 335:1107-1114.
116. Figulla HR, Gietzen F, Zeymer U, Raiber M, Hegselman J, Soballa R, et al. Diltiazem improves cardiac function and exercise capacity in patients with idiopathic dilated cardiomyopathy. Results of the Diltiazem in Dilated Cardiomyopathy Trial. Circulation 1996; 94:346-352.
117. The Danish Study Group on Verapamil in Myocardial Infarction. Secondary prevention with verapamil after myocardial infarction. Am J Cardiol 1990; 66:331-401.
118. Cleland JGF, Swedberg K, Poole-Wilson PA. Successes and failures of current treatment of heart failure. Lancet 1998; 652 (suppl 1):9-28.
119. Packer M, Meller J, Gorlin R, Herman MV. Hemodynamic and clinical tachyphylaxis to prazosin-mediated after load reduction in severe chronic congestive heart failure. Circulation 1979; 59:531-539.
120. Piller LB, Davis BR, Cutler JA, Cushman WC, Wright JT Jr, Williamson JD, et al. Validation of heart failure events in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack (ALLHAT) Participants assigned to doxazosin and chlorthalidone. Curr Control Trials Cardiovasc Med 2003; 3:1-9.
121. PROGRESS Management Committee. PROGRESS - Perindopril Protection Against Recurrent Stroke Study: characteristics of the study population at baseline. J Hypertens 1999; 17:1647-1655.
122. Staessen J, Amery A, Fagard R. Editorial review. Isolated systolic hypertension in the elderly. J Hypertens 1990; 8:393-405.
123. Franklin SS, Larson MG, Khan SA, Wong ND, Leip EP, Kannel WB, et al. Does the relation of blood pressure to coronary heart disease change with aging? The Framingham Heart Study. Circulation 2001; 103:1245-1249.
124. ACE Inhibitor Myocardial infarction Collaborative Group. Indications for ACE inhibitors in the early treatment of acute myocardial infarction. Systematic overview of individual patient data in randomized trials. Circulation 1998; 97:2202-2212.
125. Borghi C, Bacchelli S, Degli Esposti D, Bignamini A, Magnani B, Ambrosioni E, et al. Effects of the administration of an angiotensin-converting enzyme inhibitor during the acute phase of myocardial infarction in patients with arterial hypertension. Am J Hypertens 1999; 12:665-672.
126. Materson BJ, Reda DJ, Cushman WC, Massie BM, Freis ED, Kochar MS, et al. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. N Engl J Med 1993; 328:914-921.
127. Sareli P, Radevski IV, Valtchanova ZP, Libhaber E, Candy GP, Den Hond E, et al. Efficacy of different drug classes used to initiate antihypertensive treatment in black subjects. Results of a randomized trial in Johannesburg, South Africa. Arch Intern Med 2001; 161:965-971.
128. Dickerson JEC, Hingorani AD, Ashby MJ, Palmer CR, Brown MJ. Optimisation of antihypertensive treatment by crossover rotation of four major drug classes. Lancet 1999; 353:2008-2013.
129. Brown MJ, Cruickshank JM, Dominiczak AF, MacGregor GA, Poulter NR, Russell GI, et al. Better blood pressure control: how to combine drugs? J Hum Hypertens 2003; 17:81-86.
130. Adrougué HJ, Wilson H, Boyd AE, Suki WN, Eknoyan G. Plasma acid-base patterns in diabetic ketoacidosis. N Engl J Med 1982; 307:1603-1610.
131. Staessen JA, Wang JG, Birkenhäger WH. Outcome beyond blood pressure control? Eur Heart J 2003; 24:504-514.
132. 1-receptor mediated protective effect of angiotensin against acute ischaemic stroke in the gerbil. J Renin Angiotensin Aldosterone Syst 2001; 2:103-106.
133. Weber MA. The ALLHAT report: a case of information and misinformation. J Clin Hypertens 2003; 5:9-13.
134. Guidelines Committee. 2003 European Society of Hypertension/European Society of Cardiology Guidelines for the Management of Arterial Hypertension. J Hypertens 2003; 21:1011-1053.